

Oct 10 03 03:53p
OCT-10-03 FRI 9:45

Leigh Anderson
A

(202) 234-9175
FAX NO. 7034258406

P.1
P.02



RECEIVED

OCT 17 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Cassels, et al
USSN 09/801,784

Filed: March 9, 2001

For: **PEPTIDES FROM A CONSENSUS PEPTIDE OF E. COLI CSF-CFA/I
FAMILY PROTEINS**

DECLARATION UNDER RULE 132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, N. Leigh Anderson, declare that I am a scientist who has been requested to affirm the meaning of "sequence" as it usually is used to describe a sequence taken from within a larger amino acid sequence. It is my understanding that the examiner in this case has stated that the specification is unclear as to whether a sequence obtained from a peptide would be assumed to be a consecutive sequence. It would be clearly understood among those in the art that a sequence taken from a larger sequence is a consecutive sequence from the larger sequence. No other meaning would be construed by those of expertise in the art.

I further declare have no ownership or other interest in this patent application. Attached hereto is my curriculum vitae.

I further declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false

Oct 10 03 03:53p
OCT-10-03 FRI 9:45

Leigh Anderson
A

(202) 234-9175
FAX NO. 7034258406

p.2
P.03

statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement and the like so made may jeopardize the validity of this patent application and any patent that issues therefrom.

Date: 10 October 2003 By N. Leigh Anderson

N. Leigh Anderson, Ph.D. is Founder and CEO of the Plasma Proteome Institute, Washington D.C. (www.plasmaproteome.org). The Institute aims to foster a comprehensive exploration of the proteins of human blood plasma (the plasma proteome), improved quantitation of potential disease markers, and the rapid application of novel protein measurements in clinical diagnostics.

Prior to founding PPI, Dr. Anderson was Chief Scientific Officer at Large Scale Biology Corporation (Nasdaq: LSBC), whose proteomics division he founded in 1985 and led as CEO prior to its merger in 1999 with Biosource Technologies to create the current LSBC. At LSBC, he developed the first automated two-dimensional electrophoresis technology platform for proteomics research, co-led a successful IPO based largely on the proteomics technology platform (working with J.P. Morgan, Chase H&Q and Wm Blair) and grew the proteomics group into a focused scientific team of more than 60 people.

Dr. Anderson obtained his B.A. in Physics with honors from Yale and a Ph.D. in Molecular Biology from Cambridge University (England) where he worked with M. F. Perutz as a Churchill Fellow at the MRC Laboratory of Molecular Biology. Subsequently he founded (with Dr. Norman Anderson) the Molecular Anatomy Program at the Argonne National Laboratory (Chicago) where his work in the development of 2-D electrophoresis and molecular database technology earned him, among other distinctions, the American Association for Clinical Chemistry's Young Investigator Award for 1982 and the 1983 Pittsburgh Analytical Chemistry Award.

The Andersons together undertook the first systematic "proteomics" investigations of human plasma by 2-D electrophoresis (published in PNAS in 1977), and analyzed plasma protein microheterogeneity and the properties of plasma antibodies. At LSBC, Leigh Anderson initiated a database of plasma proteins observed by proteomics, a collaboration with Pfizer that provided early direct evidence of the utility of multiple plasma protein marker panels in the study of inflammation and anti-inflammatory drug effects, and successful efforts using immunosubtraction to remove high abundance proteins from plasma samples prior to proteome analysis. Dr. Anderson has published more than 120 scientific papers, one book and 16 patents.

Dr. Anderson is a member of the Board of Directors of Dade Behring Holdings, a global diagnostics company, and serves on the National Academy of Science's standing Committee on Emerging Issues and Data on Environmental Contaminants and the editorial boards of Molecular and Cellular Proteomics, Proteomics, the Journal of Proteome Research and Clinical Proteomics.